Gastrinomas are the most common symptomatic, malignant PET in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment. Studies are now underway, evaluating the natural history of these tumors including the a definition of factors determining prognosis and cause of death. Our studies have identified a cohort of 25% of patients in whom the gastrinomas have aggressive growth and 25% who have multiple endocrine neoplasia type 1 (MEN1). During this year information from our prospective studies was used to write a number of guideline and position papers with the North American Neuroendocrine Tumor Network and the European Neuroendocrine tumor network. In addition, a prospective study of acid secretory changes in patients post gastrinoma resection was completed showing for the first time insights into factors regulating basal secretion in this time period;a collaborative study of the ability to resect pancreatic endocrine tumors(PETs) thought to invade/encase or involve major blood vessels was completed which showed this should not be a contraindication to surgery is is currently widely thought;an epidemiological study on PETs in Japan was completed , which showed a number of important differences from the West, and a number of consensus conferences and position papers on classification/treatment of various disease aspects were published.Currently studies in progress include a study of the need for lymph node resection during surgery for prognostication and a study of the causes of death of MEN1 patients and identification of important prognostic factors.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Ueda, Keijiro; Kawabe, Ken; Lee, Lingaku et al. (2017) Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. Pancreas 46:476-481
Jensen, Robert T; Norton, Jeffrey A (2017) Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas 46:589-594
Ito, Tetsuhide; Jensen, Robert T (2017) Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 24:15-24
Oberg, Kjell; Couvelard, Anne; Delle Fave, Gianfranco et al. (2017) ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology :
Ito, Tetsuhide; Lee, Lingaku; Jensen, Robert T (2016) Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother 17:2191-2205
Ito, Tetsuhide; Jensen, Robert T (2016) Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol 3:53-66
Oberg, Kjell; Krenning, Eric; Sundin, Anders et al. (2016) A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 5:174-87
Ito, Tetsuhide; Hijioka, Susumu; Masui, Toshihiko et al. (2016) Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol :
Nilubol, Naris; Weinstein, Lee S; Simonds, William F et al. (2016) Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure. Ann Surg Oncol 23:416-23
Falconi, M; Eriksson, B; Kaltsas, G et al. (2016) ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 103:153-71

Showing the most recent 10 out of 47 publications